Managed at DHL Supply Chain Turkey’s secure facility on the European side of Istanbul, Biogen’s temperature-sensitive biopharmaceutical therapies are handled under validated 2–8°C environments. To support the expanded service portfolio, DHL Supply Chain Turkey has deployed capital to enlarge its active temperature-controlled fleet. Equipped with real-time telematics and digital condition monitoring, these dedicated vehicles ensure therapies reach healthcare institutions across Turkey under uninterrupted product integrity and full regulatory compliance (GDP).
The partnership directly supports DHL Group’s global "Strategy 2030," which prioritizes Life Sciences & Healthcare as a key growth driver, while advancing Biogen’s mission to secure sustainable patient access for specialized therapeutics.
Technical Infrastructure and Service Scope
Validated Thermal Storage: Biopharmaceutical consignments are maintained within continuous 2–8°C controlled cold storage and bonded warehousing supported by 24/7 security and environmental alarms.
Active Cold-Chain Transport: Specialized refrigerated vehicles featuring integrated IoT sensors deliver real-time spatial and thermal traceability across distribution lanes directly to hospitals and medical facilities nationwide.
Integrated VAS Solutions: The facility provides secondary packaging, country-specific labeling, and compliance verification within an integrated logistics network.
Executive Commentary
Buket Cox, Managing Director of DHL Supply Chain Turkey:
“In the life sciences and healthcare sectors, logistics represents far more than physical cargo handling. Every delivery supports a patient whose outcome relies on uninterrupted access to therapy. Product integrity, quality, and regulatory compliance are therefore fundamental to our operations. Expanding our collaboration with Biogen Turkey to encompass temperature-controlled warehousing and active cold chain distribution establishes a resilient logistics framework for sensitive therapeutics nationwide.”
Ömer Faruk Arslan, Country Manager of Biogen Turkey:
“At Biogen Turkey, our commitment is ensuring individuals living with rare diseases maintain continuous access to transformative therapies. Reliable and robust supply chain execution is essential to achieving this goal. Converting breakthroughs in neurology, neuropsychiatry, and immunology into real-world patient impact requires a dependable healthcare ecosystem operated under exacting quality standards. Expanding our partnership with DHL Supply Chain reinforces our patient-centric strategy, safeguarding timely delivery under validated clinical conditions.”
